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Enzyme-Assisted Suicide: Molecular Basis for the
Antifungal Activity of 5-Hydroxy-4-Oxonorvaline by
Potent Inhibition of Homoserine Dehydrogenase
to drug resistance [3, 4]. Consequently, the discovery
of new antifungal agents and the identification of appro-
priate targets are pressing. One promising antifun-
gal compound is 5-hydroxy-4-oxonorvaline [HON; (S )-
2-amino-4-oxo-5-hydropentanoic acid; RI-331], which
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and Gerard D. Wright1,* was isolated from Streptomyces species over 40 years
ago in an antimycobacterial screen [5] (Figure 1A). HON1Antimicrobial Research Centre
and Department of Biochemistry has been shown to have in vitro effects against the
human fungal pathogen Cryptococcus neoformans [6]McMaster University
Hamilton L8N 3Z5 and the plant pathogen Cladosporium fulvus [7]. Further-
more, in vivo efficacy against the human pathogen Can-2 Department of Biochemistry
McGill University dida albicans has also been shown. Treatment of mice
with systemic candidiasis increased survival rates dra-Montreal H3G 1Y6
3 Department of Chemistry matically (100% with 100 mg/kg twice daily over 14 days)
while demonstrating no toxicity (LC50  5000 mg/kg) [6].McMaster University
Hamilton L8S 4M1 Early reports identified the target of HON to be homo-
serine dehydrogenase (HSD) [8], which catalyzes the4 Department of Chemistry
University of Waterloo conversion of L-aspartate -semialdehyde (ASA) to
L-homoserine (Hse; Figure 1B). HSD is part of the aspar-Waterloo N2L 3G1
5 Crompton Corporation tate pathway that synthesizes the essential amino acids
methionine, threonine, and isoleucine in fungi. This path-Guelph N1E 5L7
6 Department of Microbiology and Immunology way is absent in mammals making it an excellent target
for novel antifungal agents. The effect of HON for treat-McGill University
Montreal H3A 2B4 ment of systemic mycoses is remarkable given the unim-
pressive reversible inhibition characteristics of HSD inCanada
the steady state with mM affinity in the metabolically
forward, Hse-forming direction (Ki of 2 mM) [9]. This
tepid affinity of antibiotic for the target would appear toSummary
be inconsistent with a compound capable of arresting
cell growth. The observation that the affinity was im-The structure of the antifungal drug 5-hydroxy-4-oxo-
norvaline (HON) in complex with its target homoserine proved in the reverse, i.e., Hse-oxidizing direction, and
that this inhibition was potentiated by the presence ofdehydrogenase (HSD) has been determined by X-ray
diffraction to 2.6 A˚ resolution. HON shows potent in the cosubstrate NADP [9], suggested a more complex
mechanism of inhibition than simple dissociation. Usingvitro and in vivo activity against various fungal patho-
gens despite its weak (2 mM) affinity for HSD in the a combination of structure activity relationships, spec-
troscopic studies, and X-ray crystallography, we havesteady state. The structure together with structure-
activity relationship studies, mass spectrometry ex- established the mechanism of HSD inhibition by HON,
and consequently the molecular basis for its antifungalperiments, and spectroscopic data reveals that the
molecular mechanism of antifungal action conferred properties.
by HON involves enzyme-dependent formation of a
covalent adduct between C4 of the nicotinamide ring
Results and Discussionof NAD and C5 of HON. Furthermore, novel interactions
are involved in stabilizing the (HON•NAD)-adduct, which
Kinetics and Chemical Prerequisites of HSDare not observed in the enzyme’s ternary complex
Inhibition by HONstructure. These findings clarify the apparent paradox
We established that HSD inhibition by HON exhibitedof the potent antifungal actions of HON given its weak
the characteristics of irreversible inactivation rather thansteady-state inhibition characteristics.
a dissociable inhibitor, including both time and concen-
tration-dependent inactivation of HSD (Figure 2), andIntroduction
that inactivation required the presence of NAD(P). Inhi-
bition of HSD by HON decreased with increasing ASAThe increasing frequency of disease resulting from
concentrations consistent with active site-directed inac-pathogenic fungi has become a serious health concern
tivation and preincubation of the inhibitor and NAD[1, 2]. The rise in fungal infections is predominantly at-
did not affect inactivation rates. Two additional HONtributable to an increase in immunocompromised indi-
analogs, isosteric L-aspartate -hydroxamate (a revers-viduals, who are especially susceptible to fungal patho-
ible inhibitor of yeast HSD [10]) and 4-oxo-L-norvalinegens, and to failure of present antifungal therapies due
(Figure 1A), were also investigated and showed no time-
dependent inactivation of HSD. This structure activity*Correspondence: wrightge@mcmaster.ca
7 These authors contributed equally to this work. analysis suggests that HON-dependent inactivation of
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Figure 1. HSD Reaction and Inhibitors
(A) Chemical structures for HON and two ana-
logs thereof.
(B) Reaction catalyzed by HSD.
HSD requires the hydroxymethylketone moiety. Further- chiometry of 1 mol [14C]-NAD:1 mol HSD at 100% en-
zyme inactivation. Electrospray mass spectrometrymore, 3-amino-pyridine adenosine dinucleotide, a non-
reactive NAD analog and competitive inhibitor of nico- performed under slightly acidic conditions (0.005% for-
mic acid) revealed a molecular mass of 78,333  100,tinamide cosubstrate binding to HSD [11, 12], was
incubated with HSD and HON, and no inactivation of corresponding to two HON molecules and two NAD
molecules bound to the HSD dimer (predicted mass:HSD was observed. A redox-active form of NAD(P) is
therefore essential for inactivation and could be involved 78,384). In the absence of HON, or under harsher, pro-
tein-denaturing, acidic or basic conditions, only the mo-in the conversion of HON to an inhibitory form.
nomeric species was detected (38,375  10). These
results indicate that HON inactivation is a consequenceStability of the HSD•NAD(P)•HON Complex
The reversibility of HON inactivation of yeast HSD was of the formation of a long-lived HSD•NAD•HON ternary
complex that is sensitive to acid and base denaturation.examined by measuring the reappearance of HSD activ-
ity and by exchange of [14C]-NAD into an inactive com-
plex; however, no regain of activity or label exchange Inhibition of HSD through Adduct Formation
could be detected after room temperature incubation The requirement for oxidized nicotinamide in HSD inac-
over 28 days. Inactivation of HSD with HON in the pres- tivation and the formation of a highly stable ternary inhi-
ence of [14C]-labeled NAD resulted in an observed stoi- bition complex suggested that HON could undergo
oxidized NAD(P)-dependent oxidation to generate a
potentially reactive glyoxal derivative (Figure 3, path A);
however, inhibition was not affected by the presence of
electrophile trapping agents, including glutathione and
-mercaptoethanol, and glyoxal-reactive D,L-arginine.
Alternatively, a covalent adduct could be formed be-
tween C-5 of HON and position C-4 of the nicotinamide
ring of NAD (Figure 3, path B). We found evidence for
such an adduct in an increase in absorbance in the
320–340 nm region in the inhibited ternary complex and
by inactivation of HSD with HON and NAD enriched
with 13C at position 4 of the pyridine ring [13]. This re-
sulted in the detection of a signal at 39.39 ppm in the
13C NMR spectrum of the inactivated complex, consis-
tent with a change in C4 hybridization from sp2 in NAD
to sp3 in the predicted adduct.
Unequivocal evidence for the formation of a covalent
adduct between HON and NAD in the active site of
HSD was achieved with the crystallization of the inactive
Figure 2. Time-Dependent Inactivation of Yeast HSD by HON complex and the determination of its atomic structure
by X-ray diffraction methods (Table 1 and Figure 4A).Residual HSD activity was measured at specific times after HSD
(0.12 M) incubation with 0 (O), 0.12 (), 0.6 (), 1.2 (), 2.4 (), Continuous electron density is observed between the
and 4.8 mM () HON in the presence of 0.5 mM NAD and 100 mM NAD and HON moieties, which is consistent with forma-
HEPES (pH 7.5) at room temperature (25C). Lines represent the tion of an adduct that includes a bond between the C-4
results of linear regressions. A plot of first order inactivation rate
atom of the nicotinamide ring and C-5 of HON (Figureconstants (kobs) versus HON concentration data resulted in a hyber-
4B). The NAD moiety of the adduct interacts with HSDbolic curve and estimation of the maximal rate of inactivation (kinact)
of 0.20  0.03 min1 and dissociation constant of KI 	 3.3  0.9. in an identical manner to that seen previously in HSD
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Figure 3. Possible Routes for HSD Inhibition
by HON that Require NAD
binary and ternary complex structures. The HON moiety understanding of the reaction mechanism employed for
adduct formation (see below) also does not enable usof the adduct is, however, positioned and oriented differ-
ently than one would expect based on the structure of to definitively predict the chirality of the adduct. There-
fore, the current model has both configurations at C5HSD in complex with Hse (Figure 4C). When comparing
HON versus Hse when bound to HSD, HON has rotated modeled with equal occupancy.
60, translated 1.3 A˚, and has altered its C2-C3 tor-
sion angle by 180, resulting in an rms distance be- Mechanism of Adduct Formation by HON
tween common atoms of 3.4 A˚. The rotation and transla- and Inhibition of HSD
tion enables C5 of the HON moiety to be within 1.6 A˚ The 3D structure of the HON-inhibited ternary complex
of the C4 atom of the nicotinamide ring, thus forming a provides insight into the mechanism of adduct forma-
covalent bond. The altered torsion angle enables the tion. Formation of the enolate of HON in the active site
carboxylic acid group of HON to form favorable interac- of HSD bound with NAD sets up the compound for
tions within the HSD active site, which would otherwise nucleophilic attack of C5 of HON on the nicotinamide
not exist. ring at C-4 (Figure 5, path A). This would require the
Adduct formation results in the creation of a chiral assistance of an active site base, though there are no
center at the C5 atom of the HON moiety. The electron obvious candidates within the vicinity of the predicted
density for this part of the adduct does not allow us deprotonation. A more plausible scenario for adduct
to distinguish between an R or S configuration. Our formation is that the enol form of HON is the reactive
species (Figure 5, path B). For this mechanism Lys223
is required to be neutral, so as to act as a proton ac-
Table 1. Structural Statistics of the HSD•NAD•HON Complex
ceptor, thus suggesting that the pK value for its primary
Data Collection amine is lower than typical. Given that within a 6 A˚ radius
of the amine the majority of charged groups are positiveSpace group P43212
Unit cell (A˚) a 	 b 	 80.9; c 	 249.0 (Lys117, NAD, helix J dipole versus Asp219), a reduc-
Resolutiona (A˚) 2.6 (2.69–2.60) tion in the pK value for Lys223 is not unexpected. An
Completeness (%) 94.6 (72.0) analogous mechanism that also incorporates a neutral
Reflections (working/test) 24,083/2,356
lysine, which acts as a base, has been proposed forRmergeb (%) 8.1 (25.7)
NAD-ketone adduct formation in Drosophila alcohol de-
I/ 16.5 (4.0)
hydrogenase [14].
Refinement and Model Statistics This pathway accounts for the observed high Ki value,
Rcrystc (%) 23.2 as the enol concentration is expected to be small.
Rfreed (%) 29.5 Neither we nor previous investigators [15, 16] that
Rmsd bonds A˚ 0.007 have isolated or synthesized HON have detected signifi-
Rmsd angles (o) 1.4
cant enol content in aqueous solution. To obtain anNo. of protein atoms 5420
approximate value for the enol content, we subjectedNo. of ligand atoms 55
the model compound 1-hydroxy-2-butanone to high-No. of solvent atoms 40
Average B factor A˚ 35.1 level ab initio minimization and energy calculations
(B3LYP/6-3111G** level) in water using a self-consis-a Number in parentheses refer to highest-resolution shell.
tent reaction field method based on a Poisson-Boltz-b Rmerge 	 |Ii  
I|/Ii, where I represents the intensities of a
multiply measured reflection hkl and 
I their average. mann approach [17–19]. The energy for the expected
c Rcryst 	 |Fo  Fc|/Fo enediol 1,2-dihydroxybut-1-ene was also calculated un-
d Rfree is the crystallographic R factor calculated from 9.8% of the der identical conditions. Using this approach, it was
data not included in refinement.
determined that the keto form is approximately 13.6
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Figure 4. Crystal Structure of HSD with (HON•NAD)-Adduct in the Active Site
(A) Overall fold of the HSD dimer, highlighting the location of the adduct.
(B) Fo  Fc SA-omit map of the (HON•NAD)-adduct contoured at 2.
(C) Stereo diagram of the active site of HSD with bound (HON•NAD)-adduct. Also shown in overlay is the structure of HSD with bound NAD
analog and HSE. For clarity, for those parts of the structures that do not differ significantly between the two models, only the adduct structure
is shown in gray. Residues and side chains with different conformations are colored purple for the HSE-bound structure and gold for the
(HON•NAD)-adduct bound structure. Hydrogen bonds are illustrated by dash lines, and the R and S configuration at the C5 atom of the HON
moiety are shown using transparencies. Figure was prepared with Molscript [28], Conscript [29], and Raster 3D [30].
kcal/mole more stable than the enediol in water. This which results in effectively irreversible inhibition. At least
two, and possibly three, factors play a role in the highcorresponds to a predicted 1.1  108% enol content
for HON in water. This is consistent with values experi- affinity of the adduct for the enzyme. First, because the
(HON•NAD)-adduct can be considered a bimolecularmentally found for similar types of ketones.
The structure of the HSD•(HON•NAD)-adduct com- mimic of the two substrates, its binding constant is the
first approximation of the product of the binding con-plex also provides a rational explanation for the ob-
served tight binding behavior afforded by the inhibitor, stants for the individual substrates. Second, the HON
Suicide Inhibition of Homoserine Dehydrogenase
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Figure 5. Alternate Mechanisms of Adduct
Formation Involving Bond Creation between
NAD(P) and the HON Enolate or Neutral Enol
Path A, HON enolate; path B, neutral Enol.
moiety forms several strong interactions with HSD (Fig- the development of compounds that target HSD with
improved drug-like properties for the treatment of se-ure 4C). Specifically, the carboxylate group of HON
forms a hydrogen bond with the amide backbone of rious fungal infections.
Gly175. This interaction is further strengthened due to
Experimental Proceduresthe specific location where it occurs, i.e., Gly175 is posi-
tioned at the base of helix J implying that the helix dipole
Synthetic Chemistry
will additionally favorably interact with the negatively HON and 4-oxo-L-norvaline were synthesized from the common
charged carboxylic acid group of the HON moiety. Fi- intermediate (S )-3-benzyloxycarbonyl-5-oxo-4-oxazolidineacetic
nally, the tight binding behavior can be readily rational- acid [20]. Preparation of the 3-benzyloxycarbonyl-4-(3-diazo-2-oxo-
propyl)-5-oxazolidinone was accomplished in the same fashion asized if the conformation of the (HON•NAD)-adduct
for the reported glutamate homolog using thionyl chloride followedclosely mimics the transition state for the reaction cata-
by reaction with diazomethane [20]. For the synthesis of 4-oxo-lyzed by HSD. However, previous mutagenesis data,
norvaline, this diazo compound was reacted with hydrogen iodide
geometric considerations for hydride transfer, and the in chloroform to produce the protected methyl ketone, which was
observed differences between Hse and HON when deprotected to 4-oxo-L-norvaline by either catalytic hydrogenation
bound to HSD [12] are not fully consistent with the ad- using ammonium formate and Pd/C in methanol [21, 22] or 30%
HBr in acetic acid [23]. For the synthesis of HON, the diazo com-duct being a true analog of the predicted transition state,
pound was reacted with glacial acetic acid [24] at 70C for 2 hr,though they do not rule it out.
and purification yielded 3-benzyloxycarbonyl-4-(3-acetoxy-2-oxo-
propyl)-5-oxazolidinone. Reaction of the acetoxy compound with
Significance 30% HBr in acetic acid [23] (23C for 30 min) to cleave the oxazolidi-
none followed by hydrolysis of the acetate in 6 N HCl [15] at 23C
for 4 days yielded HON.HON is a promising antimycotic agent that has shown
[13C]-NAD was prepared as previously described [13]. [14C]-NADefficacy in both in vitro and in vivo tests against human
was purchased from New England Nuclear.fungal pathogens [6]. The mechanism of action of HON
is through inhibition of HSD. Specifically, HON forms
Mass Spectrometry
an adduct with the cofactor NAD(P) in the active site Positive ion electrospray mass spectrometry of HON-inactivated
of HSD. The (HON•NAD(P))-adduct has two unusual HSD was performed by at the McMaster Regional Centre for Mass
and surprising properties. First, it remains effectively Spectrometry. HSD was denatured with 5% CH3CN and injected on
a Micromass Quattro-LC instrument using CH3CN/H2O (1:1) as airreversibly bound to the HSD active site, making HON
solvent.an enzyme-assisted suicide inactivator. Second, the
(HON•NAD(P))-adduct appears to be unstable outside
13C-NMR Spectroscopythe context of the HSD active site, because all attempts
A solution of HSD (15 mg, 0.38 mol) in TAPS (700 l) was added
to isolate the adduct have failed. This detailed dissec- to [13C]-NAD (0.25 mg, 0.38 mol) in 1.5 ml microfuge tube. To the
tion of the mechanism of HSD inhibition by HON ex- solution, 38 l of 20 mM solution of HON (0.111 mg, 0.75 mol) was
then added, and after mixing, the resulting solution was transferredplains how this antimycotic compound, which displays
to a NMR tube. Carbon-13 NMR spectra were recorded on a Brukerpoor binding affinity in the steady state, is able to
Avance DRX-500 spectrometer at 125.771 MHz using a 5 mm broad-arrest fungal growth. While favorable pharmacokinetic
band inverse probe with triple axis gradient capability. The spectraproperties, such as nontoxicity, are promising, in vivo
were acquired over a 28.986 kHz spectral width in 32K data points
mouse studies suggest that dosage requirements are (0.565 s acquisition time). Spectra that were acquired in 1 hr typically
prohibitive [6]. The elucidation of the mechanism by required 3300 scans while the overnight spectrum was acquired in
50,000 scans. The 13C pulse width was 6.0 s (40 flip angle). Awhich HON confers antifungal properties will enable
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relaxation delay of 0.5 s was used. The FIDs were processed using 4. Loeffler, J., and Stevens, D.A. (2003). Antifungal drug resistance.
Clin. Infect. Dis. 36, S31–S41.exponential multiplication (line broadening, 4.0 Hz) and zero filled
to 64K before Fourier transformation. 5. Tatasuoka, S., Miyake, A., Hitomi, H., Ueyanagi, J., Iwasaki, H.,
Yamaguchi, T., Kanazwa, K.-I., Araki, T., Tsuchiya, K., Hiraiwa,
F., et al. (1961). HON, a new antibiotic produced by Strepto-X-Ray Crystallography
myces akiyoshiensis nov. sp. J. Antibiot. 14, 39–43.Crystals of the (HON•NAD)-adduct were grown under conditions
6. Yamaguchi, H., Uchida, K., Hiratani, T., Nagate, T., Watanabe,that were similar to published crystallization conditions for the te-
N., and Omura, S. (1988). RI-331, a new antifungal antibiotic.tragonal crystal form of HSD [11] with the exception of the addition
Ann. N Y Acad. Sci. 544, 188–190.of five molar excess HON to the protein solution and overnight
7. Yamaki, H., Yamaguchi, M., and Yamaguchi, H. (1992). Mecha-incubation prior to crystallization. Diffraction data were collected at
nism of the antifungal action of (S) 2-amino-4-oxo-5-hydroxy-the X8C beamline of the National Synchrotron Light Source, Brook-
pentanoic acid, RI-331. In Synthesis and Chemistry of Agro-haven National Laboratories using a Quantum 4 ADSC CCD detec-
chemicals III, D.R. Baker, J.G. Fenyes, and J.J. Steffens, eds.tor. Data reduction and scaling were performed with the HKL [25]
(Washington, DC: American Chemical Society), pp. 428–442.suite of data processing programs. As a starting model for refine-
8. Yamaki, H., Yamaguchi, M., Suzuki, H., Nishimura, T., Saito, H.,ment, the crystal structure of HSD complexed with NAD (excluding
and Yamaguchi, H. (1990). The mechanism of antifungal actionsolvent molecules; pdb accession 1EBF [12]) was used. Refinement
of (S)-2-amino-4-oxo-5-hydroxypentanoic acid, RI-331: the inhi-was carried out using CNS [26] and included rigid body, positional,
bition of homoserine dehydrogenase in Saccharomyces cere-bulk solvent correction, grouped B factor, and restrained individual
visiae. Biochem. Biophys. Res. Commun. 168, 837–843.B factor refinement. Manual model rebuilding was carried out with
9. Yamaki, H., Yamaguchi, M., Tsuruo, T., and Yamaguchi, H.the program O [27], guided by A-weighted Fo  Fc, 2Fo  Fc, and
(1992). Mechanism of action of an antifungal antibiotic, RI-331,simulated annealing omit maps. Initial electron density maps re-
(S) 2-amino-4-oxo-5-hydroxypentanoic acid: kinetics of inacti-vealed that only one of the two available active sites in dimeric HSD
vation of homoserine dehydrogenase from Saccharomyces cer-was occupied (Figures 4A and 4B), analogous to the structure of
evisiae. J. Antibiot. 45, 750–755.HSD with bound NAD [12]. These maps further showed that in
10. Jacques, S.L., Ejim, L.J., and Wright, G.D. (2001). Homoserineaddition to a NAD cofactor this active site was occupied by a species
dehydrogenase from Saccharomyces cerevisiae: kinetic mech-
that was too large to be solvent and which was located sufficiently
anism and stereochemistry of hydride transfer. Biochim. Bio-
close to the nicotinamide ring to suggest covalent linkage. Initially,
phys. Acta 1544, 42–54.
modeling of free HON was attempted, but this resulted in significant
11. DeLaBarre, B., Jacques, S.L., Pratt, C.E., Ruth, D.A., Wright,
positive peaks in the subsequent Fo  Fc maps, confirming a cova- G.D., and Berghuis, A.M. (1998). Crystallization and preliminary
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X-ray diffraction studies of homoserine dehydrogenase from
possible adducts were constructed, differing in chirality at the HON
Saccharomyces cerevisiae. Acta Crystallogr. D Biol. Crystallogr.
C5 position and modeled into the active site. Subsequent electron
54, 413–415.
density maps and monitoring of Rfree did not indicate a convincing 12. DeLaBarre, B., Thompson, P.R., Wright, G.D., and Berghuis,
preference for either configuration, and thus, the current model A.M. (2000). Crystal structures of homoserine dehydrogenase
describes the chirality of the HON C5 to be 50% S and 50% R suggest a novel catalytic mechanism for oxidoreductases. Nat.
(Figure 4C). Individual water molecules were added toward the end Struct. Biol. 7, 238–244.
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